CJC-1295 + DAC
A modified peptide analog discussed in relation to growth-hormone signaling.
A modified peptide analog discussed in relation to growth-hormone signaling.
CJC-1295 is a modified peptide designed to resemble a natural signaling hormone involved in growth-hormone release.
The “DAC” part refers to a chemical modification (drug affinity complex) intended to change how the peptide binds in the body, which can affect how long it remains in circulation. This page is strictly informational and does not provide dosing, cycle, or clinical advice. Effects vary, context matters, and more is not always better.
It is a modified signaling peptide.
DAC changes its persistence.
Longer action does not automatically mean better or appropriate.
It is described as mimicking growth-hormone-releasing hormone (GHRH), the signal your hypothalamus uses to prompt the pituitary to release growth hormone. Rather than replacing growth hormone, it is studied for whether it nudges the body's own release.
The DAC modification is intended to extend how long that signal persists — a change in duration, not a guarantee of a better outcome.
It appears in growth-hormone-axis and body-composition conversations, frequently alongside Ipamorelin, which acts through a different receptor.
Persistence and potency claims are easy to overstate. Longer-acting is a trade-off, not a free upgrade.
Discussed as an injectable in research settings. The DAC version's longer action is precisely why route, context, and professional oversight matter — none of which this page substitutes for.
This content is for informational and educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before making decisions related to your health.
